Biomarkers to predict the efficacy of Infliximab in the Patients with Inflammatory Bowel Disease

Background : Infliximab (IFX) is one of therapeutic antibodies targeting to tumor necrosis factor alpha (TNF). It is commonly used against autoimmune disorders such as inflammatory bowel disease (IBD) including Crohn's disease and Ulcerative colitis. However, the production of anti-drug antibodies (ADAs) due to its immunogenicity is one of the problems in the clinical use of IFX. ADA binds to IFX to decrease blood concentration of IFX, and causes the loss of response. In this study, we examined serum levels of IFX, TNF and ADA against IFX in IBD patients to identify the biomarkers predicting the efficacy of IFX.